From scarcity to scale: Solving the patient access challenge in precision medicine

Precision medicine is transforming drug development by enabling therapies to be matched more closely to the patients most likely to benefit. But the specificity that makes these therapies possible also creates significant challenges for clinical trials. Eligible patients may represent only a small fraction of the broader disease population, while fragmented diagnostic pathways, inconsistent biomarker testing, referral gaps, geographic barriers and participation burden can make them even harder to identify, enroll and retain.

This white paper explores why solving patient scarcity requires a more complete understanding of the patient journey—from diagnosis and biomarker testing through referral, enrollment and study completion. Discover how patient pathway mapping, patient-centered research and responsibly applied AI-enabled real-world evidence (RWE) help identify where patients are, uncover barriers to participation and translate those insights into more targeted recruitment, engagement and retention strategies.

Download the paper to learn how an integrated approach that connects patient insights, data and analytics, population science, clinical operations, laboratory capabilities, and diagnostic strategy can address patient access across the full precision medicine trial continuum. By bringing these capabilities together under a unified strategy, sponsors can identify potential access barriers earlier, accelerate enrollment, strengthen retention and generate higher-quality evidence for the patients most likely to benefit.